Stemirna Therapeutics

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science.

Stemirna Therapeutics specializes in the research and development of mRNA cancer individualized vaccines and miRNA-targeted cancer stem cells.

Stemirna Therapeutics was founded in 2016 by a group of Chinese scholars in Shanghai’s Zhangjiang Drug Valley. The company is headquartered in Shanghai, China.

 

Stemirna’s pipeline focuses on the development of immuno-oncology and infectious disease vaccines.

 

Stemirna, by utilizing its mRNA synthesis platform and LPP (lipopolyplex) nano-delivery platform, has co-developed a COVID-19 mRNA vaccine candidate with China’s Tongji University, and a personalized cancer vaccine candidate.

 

Stemirna is backed by Sequoia Capital China, WuXi AppTec, OrbiMed, China Merchants Medical, Healthcare Industry Equity Fund, Efund, and others. The company raised $188M in Series B round on Jun 04, 2021. This brings Stemirna's total funding to $205M to date.

 

 

  • Year founded: 2016
  • Funding Info: $205M over 3 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Shanghai
  • State: Shanghai
  • Country: China
Related businesses